Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.38 +2.1%	$0.38	$0.22 ▼ $1.30	$8.30M	1	3.64 million shs	685,614 shs
EQ Equillium	$1.90 +21.8%	$0.55	$0.27 ▼ $2.26	$113.06M	1.15	22.36 million shs	13.93 million shs
RANI Rani Therapeutics	$0.62 +13.8%	$0.53	$0.39 ▼ $3.75	$44.88M	-0.02	779,726 shs	1.11 million shs
SCYX SCYNEXIS	$0.82 +0.2%	$0.75	$0.66 ▼ $1.73	$34.21M	1.64	187,391 shs	118,474 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+2.15%	-3.53%	-20.60%	-44.90%	-61.21%
EQ Equillium	+21.79%	+66.67%	+361.17%	+367.98%	+130.95%
RANI Rani Therapeutics	+13.82%	+13.53%	+37.23%	+1.23%	-78.54%
SCYX SCYNEXIS	+0.21%	-2.85%	+11.17%	+5.15%	-54.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	2.0293 of 5 stars	3.5	2.0	2.7	0.0	0.6
EQ Equillium	0.9376 of 5 stars	1.0	5.0	2.2	1.7	0.0
RANI Rani Therapeutics	2.6506 of 5 stars	3.5	5.0	0.0	1.7	0.6
SCYX SCYNEXIS	0.9838 of 5 stars	0.0	5.0	1.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.00	Buy	$8.00	2,004.71% Upside
EQ Equillium	2.00	Hold	$1.00	-47.37% Downside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,074.46% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADIL, EQ, RANI, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/20/2025	ADIL Adial Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.26 per share	N/A
EQ Equillium	$41.10M	2.75	N/A	N/A	$0.08 per share	23.75
RANI Rani Therapeutics	$1.03M	43.57	N/A	N/A	($0.13) per share	-4.80
SCYX SCYNEXIS	$3.75M	9.12	N/A	N/A	$1.06 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.05	N/A	N/A	N/A	N/A	-191.31%	-153.59%	N/A
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-139.56%	-90.56%	N/A
RANI Rani Therapeutics	-$30.02M	-$0.91	N/A	N/A	N/A	N/A	-1,258.76%	-97.97%	N/A
SCYX SCYNEXIS	-$21.29M	-$0.40	N/A	16.32	N/A	-599.05%	-43.04%	-28.21%	11/5/2025 (Estimated)

Latest ADIL, EQ, RANI, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/13/2025	Q2 2025	ADIL Adial Pharmaceuticals	-$0.22	-$0.18	+$0.04	-$0.18	N/A	N/A
8/13/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	-$0.14	+$0.09	-$0.14	$0.15 million	$1.36 million
8/7/2025	Q2 2025	RANI Rani Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.02	5.02
EQ Equillium	N/A	1.65	2.70
RANI Rani Therapeutics	2.75	0.54	0.54
SCYX SCYNEXIS	N/A	5.20	5.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
EQ Equillium	27.05%
RANI Rani Therapeutics	30.19%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
EQ Equillium	31.60%
RANI Rani Therapeutics	45.08%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	21.83 million	20.90 million	No Data
EQ Equillium	40	59.50 million	40.70 million	Not Optionable
RANI Rani Therapeutics	110	71.87 million	39.47 million	Optionable
SCYX SCYNEXIS	60	41.92 million	39.89 million	Optionable

ADIL, EQ, RANI, and SCYX Headlines

Recent News About These Companies

Analysts Offer Predictions for SCYNEXIS FY2029 Earnings

August 21 at 2:56 AM | americanbankingnews.com

Scynexis reports Q2 EPS (14c), consensus (19c)

August 14, 2025 | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | finanznachrichten.de

SCYNEXIS Reports Improved Financials Amidst Strategic Developments

August 14, 2025 | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday

August 13, 2025 | americanbankingnews.com

SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment

August 8, 2025 | msn.com

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADIL, EQ, RANI, and SCYX Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.38 +0.01 (+2.15%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.37 -0.01 (-2.66%)

As of 08/22/2025 07:57 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Equillium NASDAQ:EQ

$1.90 +0.34 (+21.79%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.97 +0.07 (+3.74%)

As of 08/22/2025 08:00 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Rani Therapeutics NASDAQ:RANI

$0.62 +0.08 (+13.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.59 -0.03 (-5.51%)

As of 08/22/2025 07:11 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

SCYNEXIS NASDAQ:SCYX

$0.82 +0.00 (+0.21%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$0.81 0.00 (-0.37%)

As of 08/22/2025 07:33 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time